journal article Feb 16, 2021

Current treatment and recent progress in gastric cancer

View at Publisher Save 10.3322/caac.21657
Abstract
Abstract
Gastric cancer is not a top‐10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern and Western countries add to the complexity of identifying standard‐of‐care therapy based on international trials. Systemic chemotherapy, radiotherapy, surgery, immunotherapy, and targeted therapy all have proven efficacy in gastric adenocarcinoma; therefore, multidisciplinary treatment is paramount to treatment selection. Triplet chemotherapy for resectable gastric cancer is now accepted and could represent a plateau of standard cytotoxic chemotherapy for localized disease. Classification of gastric cancer based on molecular subtypes is providing an opportunity for personalized therapy. Biomarkers, in particular microsatellite instability (MSI), programmed cell death ligand 1 (PD‐L1), human epidermal growth factor receptor 2 (HER2), tumor mutation burden, and Epstein‐Barr virus, are increasingly driving systemic therapy approaches and allowing for the identification of populations most likely to benefit from immunotherapy and targeted therapy. Significant research opportunities remain for the less differentiated histologic subtypes of gastric adenocarcinoma and those without markers of immunotherapy activity.
Topics

No keywords indexed for this article. Browse by subject →

References
98
[1]
World Health Organization International Agency for Research on Cancer.GLOBOCAN 2018: Estimated Cancer Incidence Mortality and Prevalence Worldwide. Accessed June 16 2020.globocan.iarc.fr
[2]
The American Cancer Society.Cancer Statistics Center. Accessed June 16 2020.cancerstatisticscenter.cancer.org
[10]
American Institute for Cancer Research World Cancer Research Fund.Stomach Cancer. How Diet Nutrition and Physical Activity Affect Stomach Cancer Risk. Accessed November 24 2020.www.wcrf.org/dietandcancer/stomach‐cancer
[16]
Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer

Naruhiko Ikoma, Mariela Blum, Yi-Ju Chiang et al.

Annals of Surgical Oncology 10.1245/s10434-016-5409-7
[17]
National Comprehensive Cancer Network (NCCN).NCCN Guidelines Version 2.2020. Gastric Cancer. Accessed June 15 2020.www.nccn.org
[23]
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

David Cunningham, William H. Allum, Sally P. Stenning et al.

New England Journal of Medicine 10.1056/nejmoa055531
[25]
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

Marc Ychou, Valerie Boige, Jean-Pierre Pignon et al.

Journal of Clinical Oncology 10.1200/jco.2010.33.0597
[29]
[37]
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

P. van Hagen, M.C.C.M. Hulshof, J.J.B. van Lanschot et al.

New England Journal of Medicine 10.1056/nejmoa1112088
[41]
Allen CJ "Chemotherapy versus chemotherapy plus chemoradiation as preoperative therapy for resectable gastric adenocarcinoma: a propensity score‐matched analysis of a large, single‐institution experience" Ann Surg Oncol (2020)
[43]
Japanese gastric cancer treatment guidelines 2014 (ver. 4)
Gastric Cancer 10.1007/s10120-016-0622-4

Showing 50 of 98 references

Metrics
1,171
Citations
98
References
Details
Published
Feb 16, 2021
Vol/Issue
71(3)
Pages
264-279
License
View
Cite This Article
Smita S. Joshi, Brian D. Badgwell (2021). Current treatment and recent progress in gastric cancer. CA: A Cancer Journal for Clinicians, 71(3), 264-279. https://doi.org/10.3322/caac.21657
Related

You May Also Like

Global cancer statistics

Ahmedin Jemal, Freddie Bray · 2011

23,195 citations

Cancer statistics, 2019

Rebecca L. Siegel, Kimberly D. Miller · 2019

20,871 citations